Pharmaceutical manufacturers of Tenofovir

Headquartered in Mumbai, India, Lupin is a global pharmaceutical leader with a footprint across the U.S., LATAM, APAC, EMEA and India, with products distributed in over 100 markets. With a diverse portfolio of over 1,200 products, Lupin remains committed to its mission of making quality healthcare accessible to the communities we serve. Our visionary Founder, Dr. Desh Bandhu Gupta, instilled in us the importance of offering quality, affordable and innovative medicines and being a responsible corporate citizen, making a positive difference to patients, communities and the environment.

CKD Bio Corporation focuses on enhancing life through improved pharmaceuticals, drawing from a wealth of 80 years' experience in the industry. The company specializes in the production of top-quality intermediates and APIs, employing a comprehensive manufacturing process that encompasses fermentation and chemical synthesis

At Esteve Quimica, we are dedicated to the healthcare sector by providing support for the advancement and commercialization of products that enhance the health of patients. Established in 1966, our company remains privately owned despite being a part of ESTEVE, one of the largest pharmaceutical groups in Spain. Our current focus is on the development and production of small molecule intermediates and active ingredients for innovator companies, operating as a dedicated third-party contract business.

Established in 1958, Qilu Pharmaceutical is now one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures and distributes both Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs). Qilu currently has 12 subsidiaries, 11 domestic manufacturing sites and over 3,9000 employees worldwide. Qilu ranks among Top 5 in Chinese pharmaceutical industry in 2022. Dedicated to offering high-quality & trustworthy medicines to the world and improving people‘s well-being, Qilu is vigorously exporting its products to over 100 countries and regions around the world.

Chromo Labs operates as a fully integrated pharmaceutical company, engaging in international, active pharmaceutical ingredient (API), and oral solid dosage (OSD) manufacturing. With approvals from USFDA, EDQM, WHO GENEVA, COFEPRIS, ANVISA, and EUWC, Chromo API holds 19 CEP approvals and has 7 CEPs under review. Additionally, Chromo API has filed 35 USDMFs, 6 of which are currently commercialized. The company possesses a comprehensive backup API portfolio, supported by Chromo Medcare and Gensynth Pharmachem.

HEC Pharm Co has obtained approval from the FDA and EDQM as a pharmaceutical manufacturer of both active pharmaceutical ingredients (API) and dosage forms. Presently, HEC is the largest global producer of Macrolides API, including Erythromycin and its derivatives. Sunshine Lake Pharma Co, a subsidiary of HEC Pharm, was established to supply finished pharmaceuticals (dosage forms) to the markets of the United States and European Union (EU).

Reyoung Pharmaceutical Co., Ltd., established in 1966, is a modern comprehensive pharmaceutical company. Reyoung is given the title of National Trustworthy Company for Contract and Credit, Grade AAA Credit Company and Credit Company of Shandong Medical Industry. In the past 50 years, Reyoung inherits the mission “Reyoung Pharma., Benefit the public”, insists the business concept “Innovation is the basis, Product quality is first”. Never stop exploration and innovation, forging ahead with determination, and realizing the sustainable healthy development.

We specialize in premium Active Pharmaceutical Ingredients (APIs), Formulations, Innovative Drug Delivery Systems, and Specialty Chemicals using advanced technology with precision to adhere to global standards/specifications. Presently, we are recognized as one of the foremost global providers of Oncology/non-Oncology APIs, intermediates, and Formulations. Shilpa Medicare’s establishments have garnered significant regulatory endorsements from USFDA, EUGMP, TGA, PMDA, Cofepris, Anvisa, and KFDA, encompassing diverse regulatory approved manufacturing standards.

Cdymax (India) Pharma Private Limited was established in 1994. The organization's primary function involves the production, construction, or transformation of medications in pharmaceutical formulations for either human or veterinary application. CDYMAX guarantees and complies with HSE guidelines. Systems and protocols are implemented to oversee and regulate. All staff members undergo routine health assessments annually, and twice a year for oncology personnel. The wastewater treatment facility meets governmental standards.

VIATRIS™ represents a fresh approach to healthcare, dedicated to ensuring medicine accessibility, promoting sustainable practices, pioneering creative remedies, and enhancing patient results. Founded in 2020 through the merger of Mylan and Upjohn, Viatris unites top-notch scientific, production and distribution skills with established regulatory, medical and commercial proficiencies.

We are a technology-focused, multi-dimensional pharmaceutical company having state-of-the-art manufacturing capabilities in diverse therapeutic areas such as Cardiology, Diabetology, Pain Management, Dermatology, Ophthalmology, Neurology and more. We strive towards unlocking the power of science to provide access to affordable and innovative medicines to improve health outcomes and make a difference in people's lives across the globe. As we continue to champion the cause of Make-in-India through our steady expansion across various Indian states, we create job opportunities and drive social responsibility programs in education, healthcare, rural development and environmental protection to add value to our local communities. Our roadmap is to continue investing in discovering, developing, manufacturing, and commercializing innovative medicines. Meeting the growth and profitability goals through successful innovation in digital healthcare trends and commercial excellence will continue to be the driving factors over the next decade.

In just over a decade, Laurus has positioned itself as one of the largest and most innovative API producers globally. Expanding upon its established expertise in chemistry, Laurus has recently adopted full vertical integration, including a strong finished dosage capacity, dedicated capacity for backward integration, and also Synthesis R&D operations in India and the USA.

Emcure Pharmaceuticals is driven by the purpose to develop, manufacture and market a broad range of pharmaceutical products globally. Our core strength and competitive advantage lie in our established presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV among others. Emcure has launched 6 Biologics in the Domestic Market & RoW markets & they are the domestic leader in three biologics. With 350+ brands, five R&D centers and 13 manufacturing facilities established across the country, we have ensured a strong presence not just in India but also outside India with a wide network across 70+ countries. Our API facilities ensures that our supply chain is vertically integrated providing flexibility over control of manufacturing. We have cemented strategic global partnerships that are a result of alliances with local and multi-national companies which are at the helm of leadership in key therapeutic areas. The key objective of our widespread presence across markets is to constantly innovate and deliver affordable & high-quality healthcare solutions to people.

Solara is an API manufacturer focused on research and customer satisfaction, operating in over 75 countries. They specialize in producing APIs for niche therapeutic categories, including complex products like polymer-based APIs and injectable APIs. The company has a team of experienced scientists supported by 6 manufacturing facilities and 2 R&D centers. Additionally, Solara offers Contract Research and Manufacturing Services (CRAMS) from discovery to late phase commercial manufacturing. Solara Active Pharma Sciences, with roots in Strides Shasun Ltd. and Sequent Scientific Ltd., is committed to providing value-based products while prioritizing customer needs. The company has 140+ scientists working at 2 R&D centers and 4 API manufacturing facilities, all with global approvals and 2 dedicated R&D facilities.

SMS Lifesciences India Limited, headquartered in Hyderabad, India, is a research-driven company with over three decades of experience. It is a public listed leading API manufacturer, supplying to major generic and innovator firms. With a focus on APIs, the company operates four state-of-the-art facilities and provides quality alternative manufacturing solutions to multinational companies for their contract research and manufacturing needs. The company has multiple manufacturing facilities supporting a wide range and capacity of APIs and Intermediates.

Shanghai Acebright Pharmaceuticals Group Co Ltd was established in 1996. Over 12 manufacturing facilities conforming to GMP standards are situated in China and India. The company specializes in a range of Vitamin products, ARV APIs & intermediates, and oncology APIs & finished pharmaceutical products. It serves as an integrated CDMO service partner from R&D to commercial manufacturing.

Viyash embodies integrity and guidance in all aspects. As a fully-integrated pharmaceutical firm, we possess a robust collection of unique formulations, APIs, and advanced intermediates. Viyash and its affiliated companies manage 10 API/Intermediate facilities, boasting a combined capacity of approximately 2000 KL and diverse capabilities across various categories - small/large volume, potent/non-potent, regulated/semi-regulated markets. Additionally, we oversee a formulation manufacturing facility in New Jersey, USA, with a capacity of around 1.2 billion units.

Yangtze River Pharmaceutical Group, also known as YRPG, is a major pharmaceutical conglomerate based in China that was established in 1971. As of July 2019, YRPG spans over 3 million square meters and operates 14 manufacturing subsidiaries situated in various areas including Beijing, Shanghai, Nanjing, and Guangzhou. It has also established research and development as well as production facilities for innovative chemical medicine and traditional patented products.